Profiel
Denis G.
Kay is the founder of Alpha Cognition, Inc., founded in 2000, serving as Chief Scientific Officer.
Dr. Kay is the founder of Neurodyn Life Sciences, Inc., founded in 2006, serving as Chief Scientific Officer.
Former job includes Director & Chief Scientific Officer at Neurodyn, Inc. Education includes a doctorate from McGill University and undergraduate and graduate degrees from Dalhousie University.
Actieve functies van Denis Kay
| Bedrijven | Functie | Begin |
|---|---|---|
| ALPHA COGNITION INC. | Oprichter | 01-01-2000 |
Neurodyn Life Sciences, Inc.
Neurodyn Life Sciences, Inc. BiotechnologyHealth Technology Engages in identifying, validating and developing of natural bioactives for the early treatment of neurological diseases | Oprichter | 01-08-2006 |
Eerdere bekende functies van Denis Kay
| Bedrijven | Functie | Einde |
|---|---|---|
Neurodyn, Inc.
Neurodyn, Inc. Pharmaceuticals: MajorHealth Technology Provides neurological diseases detection | Hoofd Techniek/Wetenschap/O&O | - |
Opleiding van Denis Kay
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Bedrijven in privébezit | 5 |
|---|---|
McGill University
McGill University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Dalhousie University
Dalhousie University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Neurodyn, Inc.
Neurodyn, Inc. Pharmaceuticals: MajorHealth Technology Provides neurological diseases detection | Health Technology |
Neurodyn Life Sciences, Inc.
Neurodyn Life Sciences, Inc. BiotechnologyHealth Technology Engages in identifying, validating and developing of natural bioactives for the early treatment of neurological diseases | Health Technology |
Alpha Cognition, Inc.
Alpha Cognition, Inc. Financial ConglomeratesFinance Develops pharmaceutical products for treating neurodegenerative diseases | Finance |
















